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Hepatic hydrothorax is a relatively infrequent but
potentially serious complication of cirrhosis re-
sulting from the accumulation of ascitic fluid in
the chest cavity. Medical management is initially
directed at controlling ascites formation, but inva-
sive therapeutic procedures may be required if
symptoms persist. The aim of this study was to
report on the long-term efficacy and safety of
transjugular intrahepatic portosystemic shunt
(TIPS) placement to reduce portal hypertension in
12 consecutive subjects with refractory hepatic
hydrothorax. Most subjects had evidence of ad-
vanced cirrhosis of varying causes (Child-Pugh
class A, 1; B, 5; C, 6). Mean subject age was 54
years, and subjects were followed up for a mean
of 173 days (range, 7-926 days). The portosys-
temic pressure gradient after TIPS was reduced to
F12 mmHg in all cases. Periprocedural morbidity
was noted in 2 subjects, and 30-day survival after
TIPS placement was 75%. Overall, 58% of sub-
jects experienced either a complete or partial
response following TIPS placement. Subject re-
sponse did not correlate with age, baseline creati-
nine clearance, or Child-Pugh score. Cumulative
subject survival was 42%, and 4 of the 5 long-term
survivors required eventual liver transplantation.
Subject age G65 years was associated with early
mortality after TIPS placement, but this trend was
not statistically significant. All 4 subjects undergo-
ing liver transplantation required perioperative
pleural fluid drainage, but only 1 subject has
experienced recurrent effusion. We conclude that
TIPS may be a safe and effective temporizing
treatment for carefully selected patients with re-
fractory hepatic hydrothorax. However, patient
survival is limited after TIPS and is primarily
determined by availability of liver transplantation.
Copyright r 1998 by the American Association for
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H epatic hydrothorax is defined as the accumu-lation of ascitic fluid in the pleural cavity.
Hydrothorax is an infrequent complication of cir-
rhosis that occurs in approximately 5% of patients
with cirrhotic ascites.1 The effusion is typically
transudative and is localized to the right hemitho-
rax in the majority of cases. The proposed mecha-
nism of hepatic hydrothorax formation includes
the transdiaphragmatic flow of ascitic fluid across a
pressure gradient from the abdominal cavity to the
pleural space through small eventrations in the
diaphragm.2,3 Ascites is typically present to a vari-
able extent, but in a small proportion of patients it
may not be detectable because of the preferential
flow of ascitic fluid into the pleural space.4 When
attempting to establish a diagnosis of hepatic
hydrothorax, one must exclude other common
causes of transudative pleural effusion. Nuclear
scintigraphic techniques can be useful in confirma-
tion of a diagnosis of suspected hepatic hydrotho-
rax.5
The clinical management of hepatic hydrotho-
rax is similar to that of ascites and is usually
symptom driven. Initial efforts are directed at
achieving a negative sodium balance via the restric-
tion of sodium intake and the use of diuretics.
Because of the slow rate of fluid mobilization from
the pleural space, these therapies may lead to the
development of intravascular volume depletion,
prerenal azotemia, electrolyte disturbance, and he-
patic encephalopathy with little or no improve-
ment in symptoms. Although therapeutic pleurode-
sis and surgical interventions have been reported in
small series of patients, success may not be du-
rable, and serious complications have been
noted.3,6-9 Portal decompression via the creation of
a transjugular intrahepatic portosystemic shunt
(TIPS) has recently been proposed as a means of
treating patients with refractory ascites.10-13 In
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addition, several reports of the beneficial effect of
TIPS in treatment of patients with refractory he-
patic hydrothorax have recently been published.
14,15
In one series, a beneficial response was observed in
79% of treated patients, but substantial early and
late mortality was also encountered.15
The aim of this longitudinal study was to report
on the long-term efficacy and safety of TIPS for
refractory hepatic hydrothorax in 12 consecutive
subjects treated at a single center. A secondary aim
of our study was to identify potential clinical
predictors of a therapeutic response as well as
possible contraindications to TIPS for hepatic hy-
drothorax. Lastly, we also set out to determine the
impact of TIPS in liver transplant candidates with
hepatic hydrothorax and the incidence and type of
cardiopulmonary complications in those patients
undergoing subsequent liver transplantation.
Patients and Methods
Patient Population
Between June 1993 and May 1997, a total of 181 TIPS
procedures were performed at our institution: 115 for
control of variceal bleeding, 52 for control of refractory
ascites, 12 for hepatic hydrothorax, and 2 for other
indications. The medical records of the 12 patients
undergoing TIPS for refractory hepatic hydrothorax were
retrospectively reviewed. The cause of liver disease was
established by review of medical history, clinic notes,
serological tests, liver biopsy, and imaging studies. Clini-
cal data, including the indication, clinical characteristics,
procedural details, and subsequent outcome, were re-
corded. All identified subjects were then followed up
until their most recent clinical encounter, liver transplan-
tation, or death, with a mean subject follow-up of 173
days (range, 7-926 days).
All 12 consecutive subjects with hepatic hydrothorax
had become refractory to standard medical management
with sodium restriction and high-dose diuretic therapy.
Paracentesis was ineffective in controlling respiratory
symptoms in subjects with concomitant ascites. All
subjects required numerous hospitalizations due to intrac-
table respiratory symptoms with an associated decline in
their functional status despite frequent thoracentesis or
chest tube drainage prior to TIPS placement. Subjects
with known heart failure, hepatocellular carcinoma,
alcoholic hepatitis, and intrinsic renal disease were
denied TIPS for hepatic hydrothorax over the study
period. Surface or stress dobutamine echocardiography
was performed before TIPS placement in 11 of 12
subjects. Estimated creatinine clearance (Ccr) at the time
of TIPS was calculated using the Cockroft-Gault equa-
tion.16 Global liver function was assessed objectively by
calculation of the the Child-Pugh (CP) score.17
TIPS Placement
Blood products were administered to subjects with
severe coagulopathy and thrombocytopenia as needed
before the TIPS procedure. In addition, prophylactic
parenteral antibiotics were administered to all subjects
before and immediately after the procedure. A 10-mm-
diameter Wallstent (Schneider USA, Minneapolis, MN)
was placed in all subjects via a transjugular approach.18
During TIPS placement and all subsequent revisions,
portal and systemic hemodynamic pressure measure-
ments were recorded. These measurements included
inferior vena cava and portal vein pressures, from which
a portacaval pressure gradient was calculated. TIPS
patency was assessed immediately after placement with a
baseline ultrasound Doppler examination of the shunt.
Shunt patency was then followed by screening ultra-
sound Doppler examinations every 3 months. Subjects
with absence of flow by both color and power Doppler
interogation indicative of shunt thromboses and those
with shunt velocities below 50 cm/s underwent angio-
graphic revision. Other subjects with an interval change
in shunt velocity of 50 cm/s, a relative decrease of 30%
compared with normal baseline, or evidence of reversal
of flow in peripheral portal veins were referred for
angiographic revision.
Outcomes
Clinical response was determined 1 month or more after
TIPS placement. A complete response was defined as an
improvement in respiratory status with no further thora-
centesis required. A partial response was defined as an
improvement in respiratory status with a reduction in
the frequency of thoracentesis after TIPS. A nonresponse
was defined as a lack of improvement in respiratory
status or the need for thoracentesis. All subjects who
died or underwent liver transplantation less than 30 days
after TIPS did not have an adequate follow-up period for
reliable assessment of their potential response and were
classified as nonresponders. Intraoperative events and
the clinical course after liver transplantation were as-
sessed retrospectively.
Complications potentially attributable to TIPS place-
ment were defined as either procedural, early (1-30
days), or late (.30 days). Hepatic encephalopathy was
considered a complication of TIPS if it had not been
previously noted or had increased in frequency or
severity from baseline within 30 days of TIPS.
Statistics
Standard descriptive statistics for clinical variables are
reported. Pearson’s chi-squared and two-tailed t tests
were used for statistical calculations with SPSS for
Macintosh v6.1.1 software (SPSS Inc., Chicago, IL). The
survival of subjects undergoing transplantation and
other eligible subjects who did not undergo transplanta-
tion were determined using the Kaplan-Meier method
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All 12 subjects who underwent TIPS for refractory
hepatic hydrothorax over the study period met the
identified inclusion and exclusion criteria, and
they form the basis of this report. The mean
duration of subject follow-up after initial TIPS
placement to death, liver transplantation, or last
follow-up was 173 days (range, 7 to 926 days).
Four subjects were followed up for less than 30
days because of early death in 3 cases and liver
transplantation in another. Clinical characteristics
of the study population are summarized in Table 1.
Mean subject age was 54.5 years, and 3 subjects
were over age 65. The majority of subjects had
decompensated chronic liver disease of various
causes with markedly abnormal CP scores. Of note,
none of the subjects in this series carried a diagno-
sis of alcoholic hepatitis or known active alcohol
use within 1 year of TIPS placement. Eight of the
12 subjects (67%) were on the liver transplant
waiting list before TIPS.
As expected, the majority of pleural effusions
were right-sided and transudative in nature. A
single subject (subject 5) had an exudative pleural
effusion clinically consistent with hepatic hydrotho-
rax. An extensive evaluation, including repeated
pleural fluid analysis and culture as well as a
pleural biopsy, did not show other contributing
causes. Results of preprocedural cardiac studies
were unremarkable in 11 subjects. Estimated Ccr
immediately before the procedure varied from less
than 10 to 123 mL/min (Table 2) and 4 of the
subjects had moderate to severe renal impairment
with estimated Ccr ,50 mL/min. A diagnosis of
functional renal impairment in the setting of cirrho-
sis was established by a lack of known chronic
renal insufficiency, no evidence of structural or
intrinsic renal disease by renal ultrasound, the
presence of a benign urinary sediment, a low
urinary sodium concentration, and a lack of im-
Table 1. Clinical Characteristics of Subjects
(n 5 12)
Mean age 54.5 yr (range, 41–72)
Sex 4 male, 8 female




Child–Pugh class A 5 1, B 5 5, C 5 6








Table 2. Clinical Outcomes
No. Age/Sex Ccr (mL/min) CP Score Hydrothorax Response Outcome (d)
1 41/M 49 13/C None OLT (112)
2 53/F 37 10/C Complete Died (308)
3 52/F 103 9/B None OLT (10)
4* 70/F 59 8/B None Died (18)
5 44/M 127 6/A Complete OLT list (926)
6* 57/F 69 11/C Complete Died (200)
7* 72/F 36 9/B None Died (7)
8 47/F 93 12/C None Died (29)
9 50/F 53 10/C Partial Died (119)
10 45/M ,10 12/C Partial OLT (39)
11* 69/F 22 9/B Complete Died (60)
12 54/M 77 8/B Complete OLT (252)
Abbreviation: OLT, orthotopic liver transplant.
*Not a transplant candidate before TIPS.
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provement with volume expansion. A single sub-
ject (subject 10) had advanced hepatorenal syn-
drome at the time of TIPS with a serum creatinine
level of 4.5 mg/dL and marked oliguria.
TIPS Placement
A TIPS stent was successfully placed with a re-
sidual portosytemic pressure gradient of ,12 mmHg
in all 12 subjects (Table 3). The stents were initially
dilated to 10-mm diameter in all but 1 elderly
subject (subject 7) whose stent was intentionally
dilated to only 8 mm. A single stent was placed in
10 subjects, and 2 subjects required two stents in
series to create an adequately functioning shunt.
Seven shunt revisions were required in 4 subjects
over the course of this study.
Clinical Response
A complete or partial response was seen in 7 of 12
subjects (58%) (Table 2). Five subjects had a
complete response without further requirement for
therapeutic thoracentesis or chest tube drainage.
The 2 subjects with a partial response had required
therapeutic thoracentesis every 2 to 3 days in
addition to supplemental oxygen and intensive
care unit monitoring because of respiratory compro-
mise before TIPS. After TIPS, both of these subjects
were treated successfully outside of the intensive
care unit and required a total of 3 (subject 9) and 2
(subject 10) thoracenteses over 119 and 39 days,
respectively. Subject 10 required peritoneal dialysis
because of advanced hepatorenal syndrome shortly
after TIPS placement. With improvement in his
respiratory and functional status, he then under-
went successful liver and kidney transplantation
on day 39 after TIPS.
Concomitant detectable ascites of variable sever-
ity was noted in 10 of the 12 subjects at the time of
TIPS placement. Ascites subsequently improved or
became undetectable in all 8 subjects who were
followed up more than 30 days after TIPS. Surpris-
ingly, this was not associated with a reduction in
diuretic dose. In fact, 5 of the 8 subjects were able
to tolerate higher doses of diuretics to maintain
fluid balance after the procedure. Seven of the 8
subjects (88%) followed up for more than 30 days
experienced a significant improvement in respira-
tory status. However, a consistent objective im-
provement in liver function as measured by CP
scores was not observed among the responders
during follow-up (data not shown).
Three of the 5 nonresponders were followed up
for less than 30 days because of incipient death.
Because 30 or more days after TIPS may be required
for the beneficial neurohumoral and cardiovascular
changes that lead to a natriuresis, it is difficult to
determine whether any of these subjects may have
derived a clinical benefit.19,20 In 2 of our subjects
(subjects 4 and 7), death was possibly hastened by
TIPS placement as evidenced by the development
of progressive hepatic encephalopathy and coagu-
lopathy. In the other subject (subject 8), the
development of renal failure and pneumonia after-
TIPS placement precluded her from undergoing
subsequent transplantation, and she died of infec-
tious complications on day 29. There was no
apparent relationship between clinical response
and subject baseline Ccr, age, portosystemic pres-
sure gradient, and CP score (P . .10).
Cumulative subject survival was 42% over the
study period. Late deaths in 4 subjects (subjects 2,
6, 9, and 11) were related to complications of
advanced liver disease. Subject survival was inde-
pendent of baseline Ccr, CP score, or age, although
age greater than 65 did show a trend toward
statistical significance (P 5 .11) . Overall subject
survival was most greatly influenced by access to
liver transplantation. Of the 8 subjects who were
eligible and listed for transplantation, 4 underwent
the procedure after TIPS placement. The transplant
group did not differ from eligible subjects who did
not receive transplants in regard to baseline clinical
characteristics or hepatic hydrothorax response.
Median survival for the transplanted group was
773 days, compared with 214 days for the others.
Using the Kaplan-Meier survival analysis method,
Table 3. Procedural Outcomes and Portal
Hemodynamic Measurements (n 5 12)
Technical success 12/12
Portosystemic pressure gradient
Pre-TIPS 19.6 (6 5.8) mmHg
Post-TIPS 7.7 (6 2.6) mmHg
% Reduction 60.3 (6 8.5)
Shunt revisions 7 (in 4 subjects)
Occlusion* 3
Stenosis† 4
*Shunt occlusion prompted revision in subject 4 at
days 1 and 7 and in subject 5 at day 5.
†Shunt stenosis prompted revision in subject 2 on
day 162, subject 5 on day 377 and day 784, and in
subject 12 on day 56.
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there was a statistically significant difference be-
tween the two groups (P 5 .0401) by the log-rank
test. Only 1 subject (subject 5) experienced long-
term survival (926 days) without liver transplanta-
tion. Overall, 4 of the 5 subjects who responded to
TIPS but did not undergo transplantation died
within 1 year of complications of their liver disease
(Table 2).
Complications
Major procedural complications included a single
case of hemoperitoneum. This subject (subject 2)
required blood transfusions but recovered com-
pletely without other sequelae. Another subject
(subject 9) required short-term mechanical ventila-
tion because of fluid overload associated with TIPS
placement, which responded to diuretics.
The most frequent early (,30 days) complica-
tion after TIPS placement was the development of
new or worsening hepatic encephalopathy in 4 of
the subjects (33%). The encephalopathy readily
responded to medical management in 3 subjects. In
a single elderly subject (subject 4), severe hepatic
encephalopathy developed in association with pro-
gressive liver failure that resulted in death 18 days
after TIPS. Another elderly subject (subject 7)
developed ischemic liver injury and progressive
coagulopathy with multiorgan failure following
TIPS which also led to a fatal outcome at 7 days.
Other early complications included three epi-
sodes of shunt occlusion in 2 subjects. Subject 4
developed shunt thromboses at both day 1 and day
7, requiring shunt revision. No apparent anatomic
abnormality could be identified. Subject 5 devel-
oped shunt thromboses on day 5, and the shunt
was sucessfully revised.
Late complications (.30 days) after TIPS place-
ment included symptomatic shunt stenoses on four
occasions in 3 subjects (see Table 2). In all four
instances, the subjects presented with either recur-
rent pleural effusion or respiratory symptoms with
worsening ascites. A suspicion of shunt stenoses
was confirmed by ultrasound Doppler, and the
TIPS device was successfully revised angiographi-
cally with a decrease in residual portosystemic
pressure gradient to ,12 mmHg and an associated
improvement in respiratory status in all 4 cases.
Subject 5 required two late shunt revisions; on day
377, a parallel stent was placed after a persistent
gradient could not be reduced by angioplasty, and
then on day 784, the parallel shunt was revised.
Liver Transplant Recipients
The operative course and cardiopulmonary morbid-
ity of 4 subjects who underwent transplantation are
reviewed in Table 4. All subjects required perioper-
ative drainage of the hydrothorax. Diaphragmatic
defects were identified and repaired in a single
subject. All 4 subjects were successfully extubated
within 3 days of transplantation, but 1 subject
required reintubation for several days. Interest-
ingly, this subject developed rapidly reaccumulat-
ing ascites and pleural effusions immediately after
transplantation that has persisted for more than 2
years. The remaining 3 subjects are alive and well
at a mean of 519 days after liver transplantation.
Discussion
Hepatic hydrothorax represents the accumulation
of ascitic fluid in the pleural space primarily
because of the flow of ascitic fluid through small
diaphragmatic defects under a pressure gradient.
This complication has been reported to occur in
approximately 5% of patients with cirrhosis and
ascites.1 Clinical management of this entity is
driven by the development of respiratory symp-
toms and related morbidity. As with ascites, initial
therapy is directed toward improvement of fluid
balance via sodium and fluid restriction and the use
Table 4. Pulmonary Morbidity After Liver Transplantation
No. Operative Management Days to Extubation
Long-Term Outcome
(Days Post-OLT)
1 Chest tube (37 days) 2, 6 Recurrent ascites, pleural effusion (1015)
3 Fenestration closed, chest tube (34 days) 2 No effusion (704)
10 None; chest tube (days 1–5) 3 No effusion (792)
12 None; thoracentesis (day 9) 2 Minimal effusion (61)
Abbreviation: OLT, orthotopic liver transplant.
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of diuretics. Unfortunately, a minority of patients
will have persistent symptoms with rapid re-
accumulation of pleural fluid despite optimal medi-
cal therapy. Reducing concomitant ascites by large
volume paracentesis will not reliably benefit these
patients because even small amounts of ascitic fluid
can cross the diaphragm and cause respiratory
symptoms.
The contribution of previously unrecognized
pulmonary, cardiac, and pleural diseases as well as
compliance with diet and medication should be
evaluated in all patients with worsening hepatic
hydrothorax. When the effusion becomes refrac-
tory to medical management, a therapeutic thora-
centesis may be required to relieve the respiratory
symptoms. However, the long-term treatment of
these patients with percutaneous drainage is prob-
lematic because these therapies can lead to protein
depletion and electrolyte imbalance as well as
serious infectious and bleeding complications.9
Treatment with peritoneovenous shunts has been
limited to a few reports with variable results.7,8,19
Successful outcomes have also been reported with
pleurodesis with or without diaphragmatic re-
pair.3,6-8 However, most patients with hepatic hydro-
thorax have advanced liver disease, which may
prohibit surgical intervention.
Portal decompression via creation of a TIPS has
recently been proposed as a means of treating
patients with refractory ascites as well as hepatic
hydrothorax.10-14 TIPS for refractory ascites has
lead to an improved control of ascites in as many as
50% to 80% of treated patients. The neurohumoral
and cardiovascular changes after TIPS placement
and their association with clinical response are
currently under investigation.11,12,20,21 From these
studies, the importance of recognizing concomi-
tant organ dysfunction such as cardiac and kidney
disease in prediction of a poor response to TIPS for
fluid management is becoming apparent. In fact,
some authors have suggested that these factors may
represent relative to absolute contraindications to
TIPS placement for fluid control. In addition,
patients with more advanced liver disease and
advanced age appear to be at increased risk for
worsening liver function and early death after
TIPS, which may occur in as many as 7% to 45% of
treated patients.10,22
Currently, information on the use of TIPS for
refractory hepatic hydrothorax is limited to several
small series.14,15 In the earliest series, a clinical
benefit was demonstrated in all 5 treated subjects.
The importance of reducing the portosystemic
pressure gradient to ,12 mmHg was also noted in
that 3 of the subjects with shunt stenoses devel-
oped recurrent symptomatic effusions that resolved
rapidly upon shunt revision. However, the long-
term success of TIPS in this patient population
remains unknown.
In our series, a TIPS device was successfully
placed in all 12 subjects with a residual portosys-
temic pressure gradient of ,12 mmHg. A clinical
benefit from TIPS placement was realized in 58% of
treated subjects and in 88% of subjects followed up
more than 30 days. The duration of clinical benefit
after TIPS placement varied from 39 to 926 days in
the 7 responders (mean, 272 days). Not surpris-
ingly, control of concomitant ascites was improved
as well. Subject age, baseline Ccr, and CP score
failed to predict a response to TIPS or overall
patient survival. In contrast to other recent reports,
the CP score of responders did not improve in our
subjects during follow-up.15 Long-term subject
survival was principally determined by their trans-
plant status in that only 1 subject survived without
a liver transplant.
A lack of clinical improvement in respiratory
status or the need for thoracentesis was noted in 5
of the 12 subjects. Advanced age may have been a
factor in that all 3 subjects older than 65 years of
age tolerated this intervention poorly and died
within 60 days. Impaired compensation in hepatic
arterial blood flow and a poor natriuretic effect in
elderly subjects after TIPS have both been impli-
cated in the poor response observed in this sub-
group.21 In our series, the majority of subjects had
only mild to moderate renal insufficiency at the
time of TIPS. Preprocedural estimated Ccr did not
predict clinical response, although the number of
patients studied is small. Regarding other contrib-
uting factors, none of the nonresponders had
demonstrable heart disease by history or physical
examination or on preprocedural echocardiogra-
phy. Furthermore, unrecognized shunt malfunc-
tion is unlikely to have been a factor because
periodic ultrasound Doppler examination of the
TIPS device was performed in all subjects, and
shunt revision led to prompt improvement in all
identified cases. It is certainly possible that the
persistence of other factors contributing to hepatic
hydrothorax formation such as anatomical defects
of the diaphragm, hypoalbuminemia, and poor
lymphatic drainage from the liver, which are not
improved by TIPS placement, may explain some of
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the limitations of this technique. In addition,
impaired pleural fluid dynamics that can develop
in the setting of a chronic pleural effusion may play
an important role.23
The clinical outcomes of subjects undergoing
liver transplantation in our center have generally
been good. No technical difficulties caused by
problematic positioning or migration of the stent
were encountered at the time of surgery. All sub-
jects required some form of perioperative pleural
fluid drainage. The short duration of intubation
and the lack of other associated cardiopulmonary
morbidity suggest that TIPS placement before sur-
gery may have been beneficial. As already noted, 1
subject (subject 1) developed rapid reaccumula-
tion of ascites and pleural effusions shortly after
transplantation. It is possible that this subject’s
persistent ascites and pleural effusion resulted from
peritoneal dissection and lymphatic disruption at
the time of transplantation or the persistence of
diaphragmatic defects not corrected at the time of
surgery.24
Our results are similar and yet unique in several
aspects compared with the series of Gordon et al.15
Although our series had fewer patients, the overall
clinical benefit observed (58% and 79%), the early
mortality following TIPS (25% and 21%), and the
low incidence of periprocedural complications are
remarkably similar. In contrast, our surviving pa-
tients did not experience an improvement in CP
scores or serum albumin levels. This may relate in
part to differences in patient selection in that none
of our subjects had a history of alcoholic liver
disease, whereas 67% of their population had a
component of alcoholic liver disease. It is possible
that their patients had marked improvement in
portal hypertension and ascites formation with
ongoing abstinence and improved nutrition. None-
theless, overall patient survival in both series was
poor without transplantation (8% and 17%).
In summary, we conclude that 58% of subjects
undergoing TIPS for refractory hepatic hydrotho-
rax derived a clinical benefit during follow-up.
However, even in responders, long-term survival
was primarily determined by availability of liver
transplantation. Periprocedural morbidity was ac-
ceptable, although decompensation of liver func-
tion was noted in 17% of subjects within 30 days of
TIPS placement. The ‘‘malignant’’ nature of refrac-
tory hepatic hydrothorax and the poor prognosis
associated with this complication are highlighted
by the observation that overall patient survival
without liver transplantation was only 8%. There-
fore, TIPS for refractory hepatic hydrothorax may
be a useful ‘‘bridge’’ to transplantation as opposed
to a ‘‘replacement’’ for eventual transplantation.25
Subjects who went on to liver transplantation had a
low rate of perioperative and long-term cardiopul-
monary complications and have derived an excel-
lent long-term benefit.
We propose that patients with cirrhosis and
confirmed hepatic hydrothorax should initially be
treated with medical therapy whenever possible.
For the minority of patients that require repeated
thoracenteses for persistent respiratory symptoms,
exclusion of secondary causes should be under-
taken. Portal decompression via TIPS placement
may provide clinical benefit in carefully selected
patients without significant concomitant organ
dysfunction such as cardiac or intrinsic kidney
disease. Because overall survival without liver trans-
plantation is limited, the application of this tech-
nique to elderly subjects and other patients who are
not transplant candidates should be approached
with great caution.25 Future studies to identify
potential predictors of response and associated
physiological changes are needed. Establishment of
a multicenter group and/or database may be war-
ranted to further investigate the outcomes with
TIPS in this infrequent but clinically problematic
condition.
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